Bausch Health Companies

Bausch Health makes medicines for eye, stomach, and skin health. They help patients see better and manage complex digestive issues. The company sells medical products in approximately 90 countries.

Medicines for Head to Toe

• Salix: Medicines for stomach and liver health sold in the United States; includes products for conditions like irritable bowel syndrome.
• Bausch + Lomb: Eye health products including contact lenses, surgical tools, and medicines for patients worldwide.
• International Rx: Branded and generic drugs plus medical devices sold in markets outside the United States.
• Ortho Dermatologics: Prescription products for various skin conditions and aesthetic medical devices in the American market.
• Diversified Products: Portfolio of neurology, dentistry, and generic pharmaceutical products for a wide range of patient needs.

Recent Moves and Mergers

• Acquired Wuhan Shibo Zhenmei Technology Co., Ltd. in December 2025 to assume full responsibility for distribution in the Chinese market.
• Acquired DURECT Corporation in September 2025 to add a drug candidate for alcohol-associated hepatitis to the clinical pipeline.
• Purchased Whitecap Biosciences in January 2025 to expand research into therapies for glaucoma and geographic atrophy.
• Completed a transaction in December 2025 to acquire manufacturing equipment and a facility lease in Mexico for eye health production.
• Expanded the Bausch + Lomb segment through two additional business acquisitions completed during November 2025.

Global Scale and Strategy

The company maintains a global distribution network that reaches approximately 90 countries across several therapeutic areas. Internal strategies focus on implementing cost-saving programs and evaluating the potential full separation of the eye health business.

The Financial Scorecard

• Revenue reached $2.5 billion in Q1 2026, up 10.5% from the previous year.
• Operating income rose to $513.8 million in Q1 2026, representing a 76.5% increase year-over-year.
• Net loss worsened to $1.4 billion in Q1 2026, compared to a loss of $57.8 million in Q1 2025.
• Free cash flow was $83 million in Q1 2026, down 4.6% from the $87 million reported in Q1 2025.

A Shifting Healthcare Giant

Bausch Health has evolved from a generic drug provider into a diversified global healthcare company. The organization focuses on product innovation and operational efficiency while managing its debt and preparing for corporate restructuring.